Versartis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Versartis, Inc. - overview
Established
2008
Location
Redwood City, CA, US
Primary Industry
Pharmaceuticals
About
Versartis, Inc. is a biopharmaceutical company focused on developing innovative therapies for serious medical conditions, primarily targeting growth hormone deficiency and related disorders. Founded in 2008 in Redwood City, US, Versartis, Inc. specializes in developing treatments for growth hormone deficiency.
The company went public in March 2014, raising USD 126 mn from its IPO. The current CEOs are Gail McIntyre and Jeffrey Cleland. Versartis, Inc. primarily offers therapeutic solutions aimed at addressing growth hormone deficiencies.
Their flagship product focuses on enhancing growth hormone levels in affected patients, with applications in both pediatric and adult populations. The company’s products cater to healthcare providers and patients globally, supporting a range of therapeutic needs. In the most recent year, 2017, Versartis, Inc. reported revenue of USD 40.
00 mn, alongside an EBITDA loss of USD 84. 17 mn. Following its IPO on March 21, 2014, which raised USD 126 mn, Versartis, Inc. aims to expand its product offerings and enter new markets within the biopharmaceutical sector.
The company plans to invest in the development of additional therapies aimed at addressing growth disorders while seeking to penetrate emerging markets in Asia and Europe by 2025. The funds from the IPO will be utilized to support these initiatives, ensuring continued growth and innovation in their therapeutic portfolio.
Current Investors
Index Ventures, New Leaf Venture Partners, Amunix Pharmaceuticals, Inc.
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.versartis.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Versartis, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.